Collectively, our findings further emphasize previous observations from smaller series of MECs that the presence of the CRTC1/3-MAML2 fusion is associated with favorable clinical features, low-grade tumor histology, and a good prognosis [15–17, 19, 20]. This evidence concerns the gene CRTC1 and neoplasm.